3rd Ophthalmic Drug Delivery Summit

The importance of matching the right drug delivery route to the right ophthalmic disease is more pressing than ever. The 3rd Ophthalmic Drug Delivery Summit is the premier gathering for the industry to discuss and explore innovations and future directions for ophthalmic device and formulation development. Delve into the latest in-depth analysis of intravitreal, subretinal, suprachoroidal and topical delivery and explore advancements in ophthalmic pharmacology.

Captalizing on a new wave of pipeline momentum seen with the reapproval of Roche/Genentech's Susvimo, AbbVie's recent implant partnership with Ripple, and suprachoroidal delivery revolutionizing gene therapy, this summit unites 60+ clinical and preclinical ocular experts, ophthalmic device engineers, product development leaders and formulation specialists from the likes of Genentech, Bayer, Regeneron, AbbVie, Clearside, REGENXBIO, Ocular and more as they address solutions to achieve minimally invasive delivery and sustained drug release for ophthalmology.

URLs:
Website: https://go.evvnt.com/2676391-0?pid=10018
Tickets: https://go.evvnt.com/2676391-2?pid=10018
Brochure: https://go.evvnt.com/2676391-3?pid=10018

Prices:
Drug Developer Pricing - Conference + Workshop Day: USD 4197.00,
Drug Developer Pricing - Conference Only: USD 2999.00,
Solution Provider Pricing - Conference + Workshop Day: USD 5097.00,
Solution Provider Pricing - Conference Only: USD 3699.00,
Academic Pricing - Conference + Workshop Day: USD 3597.00,
Academic Pricing - Conference Only: USD 2599.00

Speakers: Keren Mano Tamir, Head of Scientific Strategy, Everads Therapy, Michael Tolentino, Chief Innovation Officer, Aviceda Therpaeutics, Viral Kansara, Vice President, Preclinical Development, Clearside Biomedical, Max Cotler, Chief Operating Officer, GelMEDIX, Apoorva Sarode, Principal Scientist, Genentech, Kim Irwin-Pack, Executive Director, Drug Delivery and Training, REGENXBIO, Moshe Weinstein, Executive Chairman, Everads Therapy, Justin Creel, Executive Director, Device Development, Genentech, Thomas Shepard, Senior Director, Implantable Drug Delivery Sciences, Alcon, Tess Abunto, Therapeutic Area Medical Director, Eye Care, AbbVie, Gillie Roth, Principal Scientist, Genentech, Peter Francis, Chief Scientific and Medical Officer, Ray Therapeutics, Peter Petrochenko, Associate Director, Regulatory Strategy, Regeneron, Fabio Baschiera, Ophthalmology Global Clinical Leader, Bayer, Melina Cavichini, Lead Medical Director, Product Development Ophthalmology, Genentech, Jian-Xing Ma, Professor of Biochemistry, Wake Forest University